Adipose triglyceride lipase is regulated by CAMKK2-AMPK signaling and drives advanced prostate cancer
Awad, D.; Pulliam, T. L.; Spradlin, M. L.; Cao, P. H.-A.; Subramani, E.; Tellman, T. V.; Ribeiro, C. F.; Pakula, H.; Ackroyd, J. J.; Murray, M. M.; Han, J. J.; Piyarathna, B.; Drake, J. M.; Ittmann, M. M.; Coarfa, C.; Farach-Carson, M. C.; Loda, M.; Eberlin, L. S.; Frigo, D. E.
Show abstract
Lipid metabolism plays a central role in prostate cancer. To date, the major focus on prostate cancer lipid metabolism has centered on de novo lipogenesis and lipid uptake with little consideration for how cancer cells access these lipids once they are created or taken up and stored. Patient-derived phosphoproteomics identified adipose triglyceride lipase (ATGL), a previously suspected tumor suppressor, as a CAMKK2-AMPK signaling target that, conversely, promotes castration-resistant prostate cancer (CRPC) progression. Phosphorylation of ATGL increased its lipase activity, cancer cell proliferation, migration, and invasion. Shotgun lipidomics and mass spectrometry imaging demonstrated ATGLs profound regulation of lipid metabolism in vitro and in vivo, remodeling membrane composition. Inhibition of ATGL induced metabolic plasticity, causing a glycolytic shift that could be exploited therapeutically by co-targeting both metabolic pathways. Together, these data nominate ATGL and intracellular lipolysis as potential therapeutic targets for the treatment of CRPC and provide insights for future combination therapies.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Androgen receptor inhibition induces metabolic reprogramming and increased reliance on oxidative mitochondrial metabolism in prostate cancer 95%
- Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer 94%
- ECM-free patient-derived organoids preserve diverse prostate cancer lineages and uncover in vitro-enriched cell types 94%
Similar papers in this journal
- DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis 96%
- A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth 95%
- GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis 94%
Similar papers in this journal
- Single-Cell Proteomics Defines the Cellular Heterogeneity of Localized Prostate Cancer 94%
- Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients 94%
- Insulin and Exercise-induced Phosphoproteomics of Human Skeletal Muscle Identify REPS1 as a New Regulator of Muscle Glucose Uptake 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.